The new Z-drugs as sedatives and hypnotics.
Wynn
Richard L
RL
Department of Oral Craniofacial Biological Sciences, Dental School, University of Maryland, Baltimore, USA.
Bergman
Stewart A
SA
D000081:Acetamides / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D053961:Azabicyclo Compounds; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000378:metabolism; D004347:Drug Interactions; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D010879:Piperazines / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D011725:Pyridines / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D011743:Pyrimidines / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D011963:Receptors, GABA-A / Q000378:metabolism; D000077334:Zolpidem
D000081:Acetamides; D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; D011725:Pyridines; D011743:Pyrimidines; D011963:Receptors, GABA-A; C515050:zopiclone; D000077334:Zolpidem; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C085665:zaleplon